FNBTCON
AQST icon

First National Bank & Trust Co of Newtown’s Aquestive Therapeutics AQST Stock Holding History

First National Bank & Trust Co of Newtown’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4K Hold
15,000
– – 0.01% 155
2026
Q1 		$62.3K Hold
15,000
– – 0.01% 142
2025
Q4 		$96.9K Hold
15,000
– – 0.02% 139
2025
Q3 		$83.8K Hold
15,000
– – 0.02% 137
2025
Q2 		$49.5K Buy
+15,000
New +$43K 0.01% 135

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return

First National Bank & Trust Co of Newtown's AQST Position: Q2 2026 in Review

First National Bank & Trust Co of Newtown held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 15,000 shares worth $55.4K. The position accounts for 0.01% of the portfolio, ranked #155.

First National Bank & Trust Co of Newtown first reported a position in AQST in Q2 2025 and has held it in 5 quarters since. The position peaked at $96.9K in Q4 2025. 93 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • First National Bank & Trust Co of Newtown held 15,000 shares of Aquestive Therapeutics worth $55.4K as of Q2 2026.
  • First National Bank & Trust Co of Newtown left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.01% of First National Bank & Trust Co of Newtown's portfolio in Q2 2026, its #155 holding.
  • First National Bank & Trust Co of Newtown first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • First National Bank & Trust Co of Newtown's Aquestive Therapeutics position peaked at $96.9K in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on First National Bank & Trust Co of Newtown's 13F filing for Q2 2026, filed 6 Aug 2026.